Ovarian cancer

OC · Oncology · 4 drugs · 4 indications

Cancer originating in ovaries, fallopian tubes, or peritoneum. Often diagnosed at advanced stage.

Competitive Landscape (4 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
saruparib	AZN	PARP1 selective inhibitor	Small molecule	ORAL	PHASE3
Raludotatug deruxtecan	DSNKY, AZN	CDH6-directed (DXd payload)	ADC	IV	PHASE2
Lynparza	AZN, MRK	PARP inhibitor	Small molecule	ORAL	APPROVED
Elahere	ABBV	FRα-targeting ADC	ADC	IV	APPROVED

Indications (4)

FRα+ platinum-resistant ovarian cancer

Elahere APPROVED

Ovarian cancer (BRCA-mutated)

Lynparza APPROVED

Platinum-sensitive ovarian cancer

Platinum-resistant ovarian cancer

Upcoming Catalysts

R-DXd - Platinum-Resistant Ovarian - Ph2/3 - Updates (REJOICE-Ovarian01)CLINICAL

DSNKY2026

Data from Supabase · Updated 2026-03-24